Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Followi

Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company's clinical research findings.

Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 ISLEND-1 and ISLEND-2 studies of weekly islatravir/lenacapavir for HIV medication. Additionally, the companies reported negative findings from the EVOKE-03 study comparing Trodelvy with Keytruda versus Keytruda monotherapy in patients with first-line PD-L1 non-small cell lung cancer.

Moreover, on June 8, RBC Capital reaffirmed its $122 Sector Perform rating for Gilead Sciences Inc. (NASDAQ:GILD). The firm made remarks regarding the company's position in the domain of in vivo CAR-T treatment.

The firm added that in vivo CAR-T represents a possible risk to a sector that is estimated to account for 10-15% of Gilead's potential revenue. According to RBC Capital, Gilead Sciences Inc. (NASDAQ:GILD) has begun to build promising technology in the field with differentiating features and a wide approach th

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/cantor-fitzgerald-reiterates-overweight-rating-111108612.html)